CVS Health Corporation $CVS Stock: Summit Wealth Group LLC Co. Boosts Position

Summit Wealth Group LLC Co. raised its position in shares of CVS Health Corporation (NYSE:CVS) by 424.8% in the 3rd quarter, according to the company in its most recent Form 13F filing with the Securities and Exchange Commission. The firm owned 19,361 shares of the pharmacy operator’s stock after purchasing an additional 15,672 shares during the period. Summit Wealth Group LLC Co.’s holdings in CVS Health were worth $1,659,000 as of its most recent filing with the Securities and Exchange Commission.

A number of other large investors have also bought and sold shares of the company. Handelsbanken Fonder AB lifted its stake in shares of CVS Health by 83.6% during the 2nd quarter. Handelsbanken Fonder AB now owns 1,089,694 shares of the pharmacy operator’s stock valued at $112,729,000 after buying an additional 496,124 shares in the last quarter. BNP Paribas boosted its holdings in CVS Health by 105.2% in the 2nd quarter. BNP Paribas now owns 49,971 shares of the pharmacy operator’s stock worth $5,154,000 after buying an additional 25,617 shares during the period. Nykredit A S purchased a new position in CVS Health in the 2nd quarter valued at approximately $209,813,000. Oppenheimer Asset Management Inc. purchased a new position in CVS Health in the 2nd quarter valued at approximately $49,622,000. Finally, Bank of America Corp DE raised its holdings in CVS Health by 148.0% during the 2nd quarter. Bank of America Corp DE now owns 23,188,670 shares of the pharmacy operator’s stock valued at $2,398,868,000 after acquiring an additional 13,836,701 shares during the period. 80.66% of the stock is owned by hedge funds and other institutional investors.

CVS Health Stock Performance

CVS Health stock opened at $88.54 on Tuesday. CVS Health Corporation has a 1-year low of $69.51 and a 1-year high of $110.68. The company has a current ratio of 0.87, a quick ratio of 0.66 and a debt-to-equity ratio of 0.74. The firm has a market capitalization of $113.24 billion, a PE ratio of 23.42, a price-to-earnings-growth ratio of 0.84 and a beta of 0.60. The firm’s 50 day simple moving average is $91.13 and its 200 day simple moving average is $88.80.

CVS Health (NYSE:CVS) last announced its quarterly earnings results on Wednesday, August 5th. The pharmacy operator reported $2.58 EPS for the quarter, beating the consensus estimate of $1.87 by $0.71. The firm had revenue of $106.10 billion during the quarter, compared to the consensus estimate of $100.03 billion. CVS Health had a net margin of 1.18% and a return on equity of 13.12%. The business’s quarterly revenue was up 7.3% compared to the same quarter last year. During the same period last year, the firm earned $1.81 EPS. CVS Health has set its FY 2026 guidance at 7.900-8.100 EPS. As a group, analysts expect that CVS Health Corporation will post 8.02 earnings per share for the current fiscal year.

CVS Health Announces Dividend

The firm also recently disclosed a quarterly dividend, which was paid on Monday, November 2nd. Investors of record on Thursday, October 22nd were paid a dividend of $0.6650 per share. The ex-dividend date of this dividend was Thursday, October 22nd. This represents a $2.66 annualized dividend and a yield of 3.0%. CVS Health’s dividend payout ratio (DPR) is currently 70.37%.

Analyst Upgrades and Downgrades

Several research firms have issued reports on CVS. BMO Capital Markets set a $112.00 target price on CVS Health in a research report on Wednesday, September 9th. Cantor Fitzgerald reiterated a “neutral” rating on shares of CVS Health in a research report on Friday, October 9th. Wall Street Zen lowered CVS Health from a “strong-buy” rating to a “buy” rating in a research note on Monday, October 19th. Royal Bank Of Canada increased their price objective on CVS Health from $107.00 to $113.00 and gave the stock an “outperform” rating in a report on Thursday, July 9th. Finally, Leerink Partners dropped their price objective on CVS Health from $119.00 to $112.00 and set an “outperform” rating on the stock in a report on Monday, October 12th. Nineteen investment analysts have rated the stock with a Buy rating and three have assigned a Hold rating to the stock. Based on data from MarketBeat.com, the stock currently has an average rating of “Moderate Buy” and an average price target of $109.64.

CVS Health Profile

CVS Health Corporation (NYSE: CVS) is a diversified health care company that provides pharmacy, insurance and health services in the United States. Its businesses serve consumers, employers, health plans and health care providers through pharmacies, benefit programs, insurance coverage and clinical care services.

The company’s Pharmacy Services segment, led by CVS Caremark, manages prescription drug benefits for employers, insurers and government programs. CVS Pharmacy operates retail pharmacies and health-focused stores that dispense prescriptions and offer over-the-counter products, health and wellness merchandise, immunizations and related services.